Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

EMA to Seek New Home after Brexit Vote

By Ryan Bushey | June 27, 2016

Britain’s historic vote to leave the European Union (EU) last week shocked the world as financial markets plunged in reaction to a decision no one expected.

It could take years to fully comprehend what this moment signifies for the global economy, but the European Medicines Agency (EMA) is one institution facing a particularly uncertain future after this referendum.

The EMA, currently headquartered in London, will need to seek a new home that is still part of the European Union in order to continue fulfilling its regulatory duties when it comes to drug approvals, wrote Politico.  The agency serves as an important stop for drug makers seeking marketing approval for new treatments in Europe.

Sweden, Denmark, and Italy are some of the locales that have expressed interest in housing the EMA.

An estimated 840 regulators and scientists are employed by the EMA and setting up a new base in an area with strong inter-EU connections would be beneficial when it comes to expert input regarding committee meetings, according to Politico.

But this move could be complicated.  

“Industry executives fear upheaval at the EMA could snarl the EU’s drug approval process and Britain may have to develop its own domestic regulatory system, leading to further confusion,” reported Reuters.

Furthermore, a scenario of this nature would mean drug companies would prioritize launching new medications in the EU market instead of Britain’s.

The country’s exit from the EU will be a long negotiation process, but it’s still unknown how things will play out.

However, politicians and business leaders from all over the world are calling for an orderly transition.


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE